By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Elan Corporation PLC v. Intellipharmaceutics Corporation et al.
1:07-cv-00603; filed October 1, 2007 in the District Court of Delaware
Infringement of U.S. Patent Nos. 6,228,398 ("Multiparticulate Modified Release Composition," issued May 8, 2001) and 6,730,325 (same title, issued May 4, 2004), licensed to Novartis, following a paragraph IV certification as part of Intellipharmaceutics' filing of an ANDA to manufacture a generic version of Novartis' Focalin® XR (extended release dexmethylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder). View the complaint here.
Warner Chilcott Company, Inc. v. Watson Pharmaceuticals, Inc. et al.
2:07-cv-04697; filed October 1, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,667,050 ("Chewable Oral Contraceptive," issued December 23, 2003) following a paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Warner Chilcott's Femcon Fe® (formerly Ovcon® 35 Fe, norethindrone and ethinyl estradiol tablets, and ferrous fumarate tablets, used for oral contraception). View the complaint here.
Eli Lilly and Company v. Aurobindo Pharma Ltd.
1:07-cv-05488; filed September 28, 2007 in the Northern District of Illinois
Infringement of U.S. Patent No. 5,658,590 ("Treatment of Attention-Deficit/ Hyperactivity Disorder," issued August 19, 1997) following a paragraph IV certification as part of Aurobindo's filing of an ANDA to manufacture a generic version of Lilly's Strattera® (atomoxetine hydrochloride, used to treat attention-deficit/hyperactivity disorder). View the complaint here.
Hoffmann-La Roche Inc. v. Genpharm Inc. et al.
2:07-cv-04661; filed September 28, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 7,192,938 ("Method of Treatment Using Bisphosphonic Acid," issued March 20, 2007) and 6,294,196 ("Pharmaceutical Composition Containing Diphosphonic Acid or Salt Thereof," issued September 25, 2001) following a paragraph IV certification as part of Genpharm's filing of an ANDA to manufacture a generic version of Roche's Boniva® (ibandronate sodium, used to treat post-menopausal osteoporosis). View the complaint here.
Sanofi-Aventis et al. v. Torrent Pharma Inc. et al.
1:07-cv-00969; filed September 27, 2007 in the Western District of Michigan
Infringement of U.S. Patent Nos. 4,661,491 ("Alfuzosine Compositions and Use," issued April 28, 1987) and 6,149,940 ("Tablet with Controlled Release of Alfuzosine Chlorhydrate," issued November 21, 2000) following a paragraph IV certification as part of Torrent's filing of an ANDA to manufacture a generic version of Sanofi-Aventis' Uroxatral® (alfuzosin hydrochloride, used to treat benign prostatic hyperplasia). View the complaint here.
Sepracor Inc. et al. v. Orchid Chemicals & Pharmaceuticals Ltd. et al.
3:07-cv-04623; filed September 26, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 7,211,582 ("Methods for treating urticaria using descarboethoxyloratadine," issued May 1, 2007), 7,214,683 ("Compositions of Descarboethoxyloratadine," issued May 8, 2007), and 7,214,684 ("Methods for the Treatment of Allergic Rhinitis," issued May 8, 2007), licensed to Schering-Plough, following a paragraph IV certification as part of Orchid's filing of an ANDA to manufacture a generic version of Schering-Plough's Clarinex® (desloratidine, used to treat allergies). View the complaint here.
Comments